RenoVō® is a liquid, acellular, equine amniotic tissue allograft comprised of amnion and amniotic fluid, intended to cover and protect tissues. It is cryopreserved and provided frozen in three volumes.
Item Number Size
RV-010150 1.5 cc
RV-010300 3.0 cc
RV-010500 5.0 cc
Amnion and amniotic fluid are rich sources of biologically active factors involved in tissue regeneration with reported anti-inflammatory, anti-bacterial, re-epithelialization, and anti-fibrotic properties1, 2. Amniotic tissues contain key growth factors, amino acid, hyaluronic acid, proteoglycans, and extracellular matrix proteins recognized as intrinsic to the complex tissue healing process.
Biological Factors Identified in RenoVō®
IL-1ra
Interleukin-1 receptor antagonist: Potent anti-inflammatory cytokine. Inhibits the activity of interleukin-1 related immune and inflammatory responses.
IL-8
Interleukin-8: Potent anti-inflammatory cytokine. Inhibits the activity of interleukin-8 inflammatory response.
IL-10
Interleukin-10: Potent anti-inflammatory cytokine. Inhibits the activity of interleukin-10 inflammatory response.
MCP-1
Mitogenic Chemotaxis Protein-1: Plays a role in mediating peripheral nerve injury-induced neuropathic pain.
TIMP-2
Tissue Inhibitor of Metalloproteinase-2: Potent anti-fibrotic protein. Inhibitor of matrix matalloproteinases and tissue degradation.
VEGF
Vascular Endothelial Growth Factor: Potent stimulator of angiogenesis and key player in tissue regeneration.
RenoVō® is enjoying rapid adoption as a superior alternative to autologous and other therapies. Ready availability of an allograft potentiates clinical use without having time lapse for culturing cells or harvest techniques required for PRP and other autologous therapies. Due to individual variability within products such as PRP, cytokine and growth factor profiles can vary dramatically between patients. The reproducibility of each donor tissue also offers a more homogeneous protein concentration and product consistency in comparison to other regenerative modalities. RenoVō® is cryopreserved and maintained frozen before use, to preserve beneficial proteins that may not survive lyophilization. Clinicians currently managing injuries with PRP or autologous therapy should consider use of RenoVō® to achieve similar or improved clinical outcomes.
Consistent Protein
Profile
Average total soluble protein concentration measured in RenoVō® (n=24, determined by a third party laboratory)
High Levels of Interleukin-1 Receptor Antagonist Protein (IRAP)
When comparing the average IL-1ra concentration to other modalities, the measured average IL-1ra concentration detected in RenoVō® was 12,406 pg/mL (n=24, determined by a third party laboratory) compared to 1,600 pg/mL in Pro-Stride, 8,200 pg/mL in IRAP-II, and 10,900 pg/mL in IRAP ProEAS (Arthrex® VetSystems, vLA1-000004-en-US_A)
The RenoVō® Advantage
RenoVō®
• Amniotic tissue allograft
• Allogeneic
• Cryopreserved
• Versatile storage conditions
• Supplied in 1.5 cc, 3.0 cc, 5.0 cc volumes
• High concentrations of Interleukin-1 receptor antagonist protein
• High levels of growth factors/cytokines
• Consistent protein profile
• Aseptically manufactured and sterility tested
• Readily available as an off-the-shelf product
• Single administration
• Moderate cost
• No donor morbidity
IRAP I/II
• Whole blood preparation
• Autologous
• Moderate to High concentration of Interleukin-1 receptor antagonist protein
• Contains growth factors/cytokines
• Variable protein profile between patients
• Time lapse from harvest to utilization
• Inherent risk of contamination during preparation
• Single to multiple administrations
• Moderate cost
• No donor morbidity
PRP
• Whole blood preparation
• Autologous
• Low concentration of Interleukin-1 receptor antagonist protein
• Contains growth factors/cytokines
• Variable protein profile between patients
• Point of care deployment
• Inherent risk of contamination during preparation
• Single to multiple administration
• Low cost
• No donor morbidity
Stem Cells
• Cell-based product
• Autologous
• Allogeneic
• Time-lapse from harvest to utilization
• Expanded cells in culture with potential loss of purity and potency
• Contains low levels of growth factors/cytokines
• Inherent risk of contamination during preparation
• Single administration
• High Cost
• Donor morbidity
Hyaluronic Acid
• Synthetic
• Readily available as an off-the-shelf product
• Single to multiple administrations
• Low cost
• No donor morbidity